374 related articles for article (PubMed ID: 17698107)
1. Lead time of prostate cancer detected in population based screening for prostate cancer in Japan.
Ito K; Yamamoto T; Miyakubo M; Takechi H; Ohi M; Shibata Y; Suzuki K
J Urol; 2007 Oct; 178(4 Pt 1):1258-63; discussion 1263-4. PubMed ID: 17698107
[TBL] [Abstract][Full Text] [Related]
2. Prostate-specific antigen kinetics in screen-detected prostate cancer in Japan.
Takechi H; Ito K; Yamamoto T; Miyakubo M; Ohi M; Suzuki K
Urology; 2008 Nov; 72(5):1111-5. PubMed ID: 18342926
[TBL] [Abstract][Full Text] [Related]
3. Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends.
Telesca D; Etzioni R; Gulati R
Biometrics; 2008 Mar; 64(1):10-9. PubMed ID: 17501937
[TBL] [Abstract][Full Text] [Related]
4. Comparison of prostate specific antigen velocity in screened versus referred patients with prostate cancer.
Meeks JJ; Thaxton CS; Loeb S; Roehl KA; Helfand BT; Catalona WJ
J Urol; 2008 Apr; 179(4):1340-3. PubMed ID: 18289590
[TBL] [Abstract][Full Text] [Related]
5. Interval cancers in prostate cancer screening: comparing 2- and 4-year screening intervals in the European Randomized Study of Screening for Prostate Cancer, Gothenburg and Rotterdam.
Roobol MJ; Grenabo A; Schröder FH; Hugosson J
J Natl Cancer Inst; 2007 Sep; 99(17):1296-303. PubMed ID: 17728218
[TBL] [Abstract][Full Text] [Related]
6. Risk of prostate cancer for young men with a prostate specific antigen less than their age specific median.
Loeb S; Nadler RB; Roehl KA; Antenor JA; Catalona WJ
J Urol; 2007 May; 177(5):1745-8. PubMed ID: 17437803
[TBL] [Abstract][Full Text] [Related]
7. Is it necessary to detect all prostate cancers in men with serum PSA levels <3.0 ng/ml? A comparison of biopsy results of PCPT and outcome-related information from ERSPC.
Schröder FH; Bangma CH; Roobol MJ
Eur Urol; 2008 May; 53(5):901-8. PubMed ID: 18262712
[TBL] [Abstract][Full Text] [Related]
8. Defining increased future risk for prostate cancer: evidence from a population based screening cohort.
Schröder FH; Roobol MJ; Andriole GL; Fleshner N
J Urol; 2009 Jan; 181(1):69-74; discussion 74. PubMed ID: 19012915
[TBL] [Abstract][Full Text] [Related]
9. Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.
Ulmert D; Serio AM; O'Brien MF; Becker C; Eastham JA; Scardino PT; Björk T; Berglund G; Vickers AJ; Lilja H
J Clin Oncol; 2008 Feb; 26(6):835-41. PubMed ID: 18281654
[TBL] [Abstract][Full Text] [Related]
10. Age adjusted prostate specific antigen and prostate specific antigen velocity cut points in prostate cancer screening.
Moul JW; Sun L; Hotaling JM; Fitzsimons NJ; Polascik TJ; Robertson CN; Dahm P; Anscher MS; Mouraviev V; Pappas PA; Albala DM
J Urol; 2007 Feb; 177(2):499-503; discussion 503-4. PubMed ID: 17222618
[TBL] [Abstract][Full Text] [Related]
11. Specificity of serum prostate-specific antigen determination in the Finnish prostate cancer screening trial.
Määttänen L; Hakama M; Tammela TL; Ruutu M; Ala-Opas M; Juusela H; Martikainen P; Stenman UH; Auvinen A
Br J Cancer; 2007 Jan; 96(1):56-60. PubMed ID: 17213825
[TBL] [Abstract][Full Text] [Related]
12. Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry.
Stattin P; Johansson R; Damber JE; Hellström M; Hugosson J; Lundgren R; Varenhorst E; Johansson JE
Scand J Urol Nephrol; 2003; 37(6):461-5. PubMed ID: 14675917
[TBL] [Abstract][Full Text] [Related]
13. [Results and participation factors to the European Randomized study of Screening for Prostate Cancer (ERSPC) with Prostate Specific Antigen: French departments of Tarn and Hérault].
Jegu J; Tretarre B; Grosclaude P; Rebillard X; Bataille V; Malavaud B; Iborra F; Salama G; Rischmann P; Villers A
Prog Urol; 2009 Jul; 19(7):487-98. PubMed ID: 19559380
[TBL] [Abstract][Full Text] [Related]
14. Biochemical progression rates in the screen arm compared to the control arm of the Rotterdam Section of the European Randomized Study of Screening for Prostate Cancer (ERSPC).
Roemeling S; Roobol MJ; Gosselaar C; Schröder FH
Prostate; 2006 Jul; 66(10):1076-81. PubMed ID: 16637077
[TBL] [Abstract][Full Text] [Related]
15. Mass screening for prostate cancer in Korea: a population based study.
Song C; Ahn H; Lee MS; Park J; Kwon TG; Kim HJ; Choi HY;
J Urol; 2008 Nov; 180(5):1949-52; discussion 1952-3. PubMed ID: 18801541
[TBL] [Abstract][Full Text] [Related]
16. Metastatic disease of screen-detected prostate cancer : characteristics at diagnosis.
Roemeling S; Kranse R; Vis AN; Gosselaar C; van der Kwast TH; Schröder FH
Cancer; 2006 Dec; 107(12):2779-85. PubMed ID: 17109445
[TBL] [Abstract][Full Text] [Related]
17. Prostate cancer risk assessment program: a 10-year update of cancer detection.
Giri VN; Beebe-Dimmer J; Buyyounouski M; Konski A; Feigenberg SJ; Uzzo RG; Hanks G; Godwin AK; Chen DY; Gordon R; Cescon T; Raysor S; Watkins-Bruner D
J Urol; 2007 Nov; 178(5):1920-4; discussion 1924. PubMed ID: 17868726
[TBL] [Abstract][Full Text] [Related]
18. [Mass screening for prostate cancer is the best approach to early diagnosis and treatment of prostate cancer].
Zhao XJ; Kong XB; Wang WH
Zhonghua Nan Ke Xue; 2003 Nov; 9(8):563-5, 568. PubMed ID: 14689882
[TBL] [Abstract][Full Text] [Related]
19. [Screening in prostate carcinoma].
Wirth MP; Spiegel T; Froschermaier SE; Manseck A
Z Arztl Fortbild Qualitatssich; 1998 Jun; 92(5):304-9. PubMed ID: 9702818
[TBL] [Abstract][Full Text] [Related]
20. Prostate specific antigen assay standardization bias could affect clinical decision making.
Loeb S; Chan DW; Sokoll L; Kan D; Maggiore J; Mikolajczyk SD; Mondo DM; Griffin CR; Catalona WJ
J Urol; 2008 Nov; 180(5):1959-62; discussion 1962-3. PubMed ID: 18801532
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
